BCG VACCINE for Bladder transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 49 adverse event reports in the FDA FAERS database where BCG VACCINE was used for Bladder transitional cell carcinoma.
Most Reported Side Effects for BCG VACCINE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disseminated bacillus calmette-guerin infection | 87 | 20.8% | 15 | 32 |
| Immune reconstitution inflammatory syndrome | 60 | 14.4% | 5 | 13 |
| Pyrexia | 39 | 9.3% | 5 | 18 |
| Drug ineffective | 35 | 8.4% | 15 | 21 |
| Off label use | 35 | 8.4% | 8 | 8 |
| Granuloma | 16 | 3.8% | 1 | 5 |
| Mycobacterial infection | 16 | 3.8% | 5 | 14 |
| Vaccination complication | 15 | 3.6% | 0 | 5 |
| Lymphadenopathy | 14 | 3.4% | 2 | 1 |
| Disease progression | 12 | 2.9% | 2 | 0 |
| Infection | 12 | 2.9% | 1 | 9 |
| Neutropenia | 12 | 2.9% | 1 | 1 |
| Skin lesion | 12 | 2.9% | 3 | 0 |
| Acute kidney injury | 11 | 2.6% | 1 | 3 |
| Bladder cancer | 11 | 2.6% | 0 | 2 |
Other Indications for BCG VACCINE
Bladder cancer (135)
Immunisation (98)
Product used for unknown indication (30)
Transitional cell carcinoma (23)
Mantle cell lymphoma (9)
Prophylaxis (9)
Bladder neoplasm (7)
Other Drugs Used for Bladder transitional cell carcinoma
GEMCITABINE (335)
CISPLATIN (252)
PEMBROLIZUMAB (251)
ATEZOLIZUMAB (195)
CARBOPLATIN (146)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119)
AVELUMAB (104)
DURVALUMAB (88)
NIVOLUMAB (80)
ENFORTUMAB VEDOTIN-EJFV (68)